Insulet | PODD - Selling And Administration Expenses


Insulet reported $344.8M in Selling and Administration Expenses for its fiscal quarter ending in June of 2026.





Selling And Administration Expenses Change Date
Abbott USD 3.6B 330M Jun/2026
Align Technology USD 462.67M 2.67M Jun/2026
AtriCure USD 82.56M 1.99M Jun/2026
Baxter International USD 735M 7M Jun/2026
Becton, Dickinson and Co. USD 1.26B 48M Jun/2026
Boston Scientific USD 1.8B 22M Jun/2026
Cardinal Health USD 1.62B 115M Jun/2026
Cooper Companies USD 676.2M 303.1M Mar/2026
Dexcom USD 358.7M 9M Jun/2026
Edwards Lifesciences USD 561.2M 39M Jun/2026
Eli Lilly USD 3.43B 496M Jun/2026
Globus Medical USD 286.82M 10.95M Jun/2026
ICU Medical USD 151.92M 2.64M Jun/2026
Inogen USD 43.77M 510K Jun/2024
Insulet USD 344.8M 27.6M Jun/2026
Integra LifeSciences USD 166.22M 12.01M Jun/2026
J&J USD 6.42B 381M Jun/2026
Medtronic 3.06B 101M Mar/2026
Merit Medical Systems USD 129.23M 18.76M Jun/2026
Roche Holding CHF 6.37B 908M Jun/2026
Solventum Corp USD 927M 144M Jun/2026
Stryker USD 2.12B 32M Jun/2026
Tandem Diabetes Care USD 111.64M 3.45M Jun/2026
Teleflex USD 213.52M 12.5M Jun/2026
West Pharmaceutical Services USD 117.6M 18.1M Jun/2026
Zimmer Biomet Holdings USD 911.6M 61.7M Jun/2026